Aminopyridines as protein kinase Cθ inhibitors

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 5, 2007, Pages 583-586

  Zhang, Dawei ^a  

^a AMGEN INC   (United States)

Author keywords

Cytokine; Immunological disorder PKC inhibitor; Type 2 diabetes

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ENZASTAURIN; INTERLEUKIN 2; MIDOSTAURIN; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C THETA; PROTEIN KINASE C THETA INHIBITOR; RUBOXISTAURIN; STAUROSPORINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; B CELL LYMPHOMA; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETIC RETINOPATHY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; IMMUNE RESPONSE; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; T LYMPHOCYTE ACTIVATION;

EID: 34248394682     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.5.583     Document Type: Article

References (12)

1. BAIER G, TELFORD D, GIAMPA L et al.: Molecular cloning and characterization of PKCθ, a human novel member of the PKC gene family expressed predominantly in hematopoietic cells. J. Bio. Chem. (1993) 268:4997-5004.
2. CHANG JD, XU Y, RAYCHOWDHURY MK, WARE JA: Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). J Bio. Chem. (1993) 268:14208-14214.
3. ALTMAN A, VILLALBA M: Protein kinase C-θ (PKCθ): it is all about location, location, location. Immunol. Rev. (2003) 192:52-53.
4. SEDWICK C: Perspective on PKCθ in T cell activation Mol. Immunol. (2004) 41:765-686.
5. LI Y, SOOS TJ, LI X et al.: Protein kinase C-θ inhibits insulin signaling by phosphorylating IRSI at Ser 1101. J. Bio. Chem. (2004) 279:45304-45307.
6. Lilly delivers promising update to wall street on strategic priorities, pipeline progress and earnings guidance. Eli Lilly & Co. Press Release (2006) December 7.
7. GOTLIB J et al.: Phase II trial of the tyrosine kinase inhibitor PKC412 in advanced systemic mastocytosis: preliminary results. Blood (2006) 108:11.
8. Investigational treatment ruboxistaurin demonstrated promise in reducing the occurrence of vision loss caused by diabetic retinopathy. Eli Lilly & Co. Pres. Release (2006) June 11.
9. CYWIN CL, DAHMANN G, PROKOPOWICZ AS III et al.: Discovery of potent and selective PKC-θ inhibitors. Bioorg. Med. Chem. Lett. (2007) 17:225-230.
10. H1 cells in experimental autoimmune encephalomyelitis. J. Immunology. (2005) 175:7635-7641.
11. TAN S-L, ZHAO J, BI C et al.: Resistance m experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C-θ-deficient mice. J. Immunology. (2006) 176:2872-2879.
12. XU Z-B, CHAUDHARY D, OLLAND S et al.: Catalytic domain of crystal structure of protein kinase C-θ. J. Bio Chem. (2004) 279:50410-50409.